What the business is, and whether it's a good one at a fair price.
Makes medical devices across infusion therapy, renal care and cardiology for hospitals in India and overseas markets. Infusion therapy accounts for 50% of revenue, with the rest coming from higher-technology segments such as renal dialysis machines and cardiology stents. It expanded internationally through European acquisitions PendraCare and Citieffe, and bought Medyneo for about USD 40,000 to use existing ANVISA licences and enter Brazil's USD 13-15 billion medical device market. FY26 stand-alone revenue was INR 1,662 crore (+4% year-on-year) with EBITDA margin of 26.8%; consolidated revenue including the acquired entities was INR 1,875 crore (+12.3%). Raw materials at 32% of revenue are the largest cost, with crude-linked inputs seeing 20% inflation in FY26 that shaved 200-300 basis points off gross margins. The Indian medical device market is 60-70% import-driven, with hospitals shifting to 60-65% insurance-based payments, creating room for domestic manufacturing.
Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from POLY MEDICURE LIMITED's filed financials and exchange disclosures
POLY MEDICURE LIMITED is a Healthcare Equipment & Supplies company listed on NSE and BSE, trading under the symbol POLYMED.
Yes. Over the trailing twelve months POLY MEDICURE LIMITED reported a net profit of ₹313 Cr on revenue of ₹1,997 Cr.
Yes. The dividend yield is 0.20% at the current price. It paid out 11% of its profit as dividend in FY26.
No. Debt stands at 0.11× equity, and it carries net debt of ₹290 Cr. That is lower than 50% of its 11 Medical Equipment & Supplies peers.
On trailing P/E, POLY MEDICURE LIMITED ranks 13 of 17 in Medical Equipment & Supplies — cheaper than 25% of them, against an industry median of 20.0×. This is a position, not a valuation judgement.
On a typical session POLY MEDICURE LIMITED moves 1.45% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by POLY MEDICURE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
